NuVasive, Inc.  

(Public, NASDAQ:NUVA)   Watch this stock  
Find more results for NUVA
33.83
+0.40 (1.20%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 33.01 - 34.07
52 week 19.74 - 39.89
Open 33.22
Vol / Avg. 254,410.00/348,047.00
Mkt cap 1.57B
P/E 214.92
Div/yield     -
EPS 0.16
Shares 46.53M
Beta 1.07
Inst. own 99%
May 14, 2014
NuVasive�, Inc. Annual Shareholder Meeting - 8:00AM EDT - Add to calendar
Apr 29, 2014
Q1 2014 NuVasive�, Inc. Earnings Conference Call - 5:30PM EDT - Add to calendar
Apr 29, 2014
Q1 2014 NuVasive�, Inc. Earnings Release - 4:00PM EDT - Add to calendar
Mar 12, 2014
NuVasive�, Inc. at Barclays Healthcare Conference - Webcast
Mar 11, 2014
NuVasive�, Inc. at Canaccord Genuity's Musculoskeletal Conference - Webcast
Mar 5, 2014
NuVasive at Goldman Sachs West Coast MedTech Bus Tour
Mar 3, 2014
Q4 2013 NuVasive�, Inc. Earnings Conference Call - Webcast
Mar 3, 2014
Q4 2013 NuVasive�, Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 3.06% 1.02%
Operating margin 7.87% 4.83%
EBITD margin - 14.04%
Return on average assets 2.02% 0.60%
Return on average equity 4.14% 1.39%
Employees 1,358 -
CDP Score - -

Address

7475 Lusk Blvd.
SAN DIEGO, CA 92121
United States - Map
+1-858-9091800 (Phone)
+1-800-4759134 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

NuVasive, Inc. is a medical device company, that focuses on developing minimally disruptive surgical products and procedures for the spine. Its marketed product portfolio focused on applications for spine fusion surgery, including biologics. Its principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery (MAS), as well as offering of biologics, cervical and motion preservation products. spine surgery product line offerings, which include products for the thoracolumbar spine, the cervical spine, and a set of motion preservation product offerings under development, are primarily used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. Its biologic product line offerings include allograft, FormaGraft, a collagen synthetic product used to aid the fusion process, and Osteocel Plus, an allograft cellular matrix containing viable mesenchymal stem cells (MSCs), to aid in spinal fusion.

Officers and directors

Alexis V. Lukianov Chairman of the Board, Chief Executive Officer
Age: 57
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Keith C. Valentine President, Chief Operating Officer
Age: 45
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Michael J. Lambert Chief Financial Officer, Executive Vice President
Age: 51
Bio & Compensation  - Reuters
Patrick W. G. Miles President - Global Products and Services
Age: 47
Bio & Compensation  - Reuters
Quentin Blackford Executive Vice President - Finance and Investor Relations
Bio & Compensation  - Reuters
Jason M. Hannon Executive Vice President - Corporate Development, General Counsel, Secretary
Age: 41
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Matthew W. Link Executive Vice President, U.S. Sales
Age: 38
Bio & Compensation  - Reuters
Mike Paolucci Executive Vice President - Global Human Resources
Bio & Compensation  - Reuters
Russell A. Powers Executive Vice President, International
Age: 43
Bio & Compensation  - Reuters
Gregory T. Lucier Director
Age: 49
Bio & Compensation  - Reuters